Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 12

1.

Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.

Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krähenbühl S.

Eur J Clin Pharmacol. 2011 Jan;67(1):63-71. doi: 10.1007/s00228-010-0893-3. Epub 2010 Sep 21.

PMID:
20857093
2.

The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.

Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F, Brosen K, Sindrup SH.

Basic Clin Pharmacol Toxicol. 2009 Apr;104(4):335-44. doi: 10.1111/j.1742-7843.2009.00378.x. Epub 2009 Feb 27.

3.

Serotonin syndrome induced by fluvoxamine and oxycodone.

Karunatilake H, Buckley NA.

Ann Pharmacother. 2006 Jan;40(1):155-7. Epub 2005 Dec 20.

PMID:
16368927
4.

Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy.

Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R.

Support Care Cancer. 2003 Feb;11(2):84-92. Epub 2002 Aug 23. Review.

PMID:
12560936
5.

Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.

Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL.

J Clin Pharmacol. 2001 Feb;41(2):224-7.

PMID:
11210406
6.

Treatment of the serotonin syndrome with cyproheptadine.

Graudins A, Stearman A, Chan B.

J Emerg Med. 1998 Jul-Aug;16(4):615-9.

PMID:
9696181
7.
9.
11.

A method for estimating the probability of adverse drug reactions.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ.

Clin Pharmacol Ther. 1981 Aug;30(2):239-45. No abstract available.

PMID:
7249508
12.

The serotonin syndrome.

Sternbach H.

Am J Psychiatry. 1991 Jun;148(6):705-13. Review.

PMID:
2035713
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk